Shariat - Figure 27
Photodynamic Diagnosis and Recurrence
FIG. 27: Florescence cystoscopy has been shown to lower the recurrence rate of bladder cancer in patients with NMI bladder cancer including also a cohort of T1 patients.[29] One randomized prospective study reported that patients who received blue-light fluorescence cystoscopy guided by hexaminolevulinate (Hexvix; Photocure ASA) had a decrease of 20% in relative risk of recurrence.[33] This means that the number needed to treat to prevent one disease recurrence is 11. A follow-up study showed that the rate of radical cystectomy was also decreased in patients who received a PDD diagnosis.[34]
References
Burger M, Grossman HB, Droller M, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol. 2013;64:846−54 http://dx.doi.org/10.1016/j.eururo.2013.03.059
Stenzl A, Burger M, Fradet Y, et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol. 2010;184:1907−13 https://doi.org/10.1016/j.juro.2010.06.148
Gakis G, Ngamsri T2, Rausch S, et al. Fluorescence-guided bladder tumour resection: impact on survival after radical cystectomy. World J Urol. 2015;33:1429−37 https://doi.org/10.1007/s00345-015-1485-8
